eFFECTOR Therapeutics, Inc. announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board?s Audit Committee. Concurrent with Ms. Loewy?s appointment, current Board member John Smither has resigned from the Board. With over 25 years of biopharmaceutical and financial executive experience, Ms. Loewy presently acts independently in providing strategic advisory services to biopharmaceutical companies.

Ms. Loewy was a cofounder and the Chief Business Officer and Chief Financial Officer of Achieve Life Sciences, prior to its acquisition by OncoGenex Pharmaceuticals, Inc. in 2017. Prior to Achieve, Ms. Loewy previously served as Chief Financial Officer of both public and private biopharmaceutical companies including Tobira Therapeutics, acquired by Allergan Inc. in 2016, Corcept Therapeutics and Poniard Pharmaceuticals. In addition to her biopharmaceutical executive roles, Ms. Loewy also served 11 years as a senior biotechnology equity research analyst at Morgan Stanley and Prudential Securities.

Ms. Loewy has also leveraged her medical and financial expertise as a founding board member of the Global Genes Project and of the KCNQ2 Cure Alliance, both non-profit patient and advocacy organizations promoting education and research into rare disease. Ms. Loewy also currently sits on the board of CymaBay Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and Phoenix Biotech Acquisition Corp. Ms. Loewy holds a B.A. from the University of California, Berkeley, and an M.B.A./M.S. from Carnegie Mellon University.